Table 3.
Variable | Nonsurvivors (n = 48) n (%) | Survivors (n = 44) n (%) | Crude OR | 95% CI | P‐Value |
---|---|---|---|---|---|
Treatment | |||||
Antitoxin | |||||
No | 18 (38.3) | 2 (4.6) | Reference | NA | |
Yes | 29 (61.7) | 42 (95.5) | 13.03 | 2.40–70.69 | <.001 |
<6 hours | |||||
No | 21 (47.7) | 9 (21.4) | Reference | NA | |
Yes | 23 (52.3) | 33 (78.6) | 3.35 | 1.25–9.00 | .011 |
Enteral nutrition | |||||
No | 21 (56.8) | 3 (7.1) | Reference | NA | |
Yes | 16 (43.2) | 39 (92.9) | 17.06 | 3.43–84.77 | <.001 |
Antimicrobial class | |||||
Β‐lactam alone | 18 (62.1) | 5 (17.9) | Reference | NA | |
Β‐lactam + other | 5 (17.2) | 16 (57.1) | 11.52 | 2.81–47.22 | .001 |
Other | 4 (13.8) | 3 (10.7) | 2.70 | 0.45–16.26 | .278 |
Metronidazole | 2 (6.9) | 4 (14.3) | 7.20 | 1.01–51.39 | .049 |
Oxygen | |||||
No | 28 (62.2) | 34 (82.9) | Reference | NA | |
Yes | 17 (37.8) | 7 (17.1) | 0.34 | 0.12–0.97 | .034 |
IV fluids | |||||
No | 5 (10.4) | 14 (32.6) | Reference | NA | |
Yes | 43 (89.6) | 29 (67.4) | 0.24 | 0.07–0.78 | .010 |
Other meds | |||||
No | 9 (19.6) | 16 (38.1) | Reference | NA | |
Yes | 37 (80.4) | 26 (61.9) | 0.40 | 0.15–1.06 | .056 |
Ophthalmic oint. | |||||
No | 16 (35.6) | 25 (59.5) | Reference | NA | |
Yes | 29 (64.4) | 17 (40.5) | 0.38 | 0.15–0.92 | .026 |
Skin ointment | |||||
No | 41 (91.1) | 32 (76.2) | Reference | NA | |
Yes | 4 (8.9) | 10 (23.8) | 3.20 | 0.89–11.55 | .060 |
Physical therapy | |||||
No | 18 (40) | 32 (76.2) | Reference | NA | |
Yes | 27 (60) | 10 (23.8) | 0.21 | 0.08–0.57 | .001 |
Turning | |||||
No | 19 (42.2) | 32 (76.2) | Reference | NA | |
Yes | 26 (57.8) | 10 (23.8) | 0.23 | 0.09–0.62 | .001 |
Sustained recumbency | |||||
No | 8 (16.7) | 35 (79.6) | Reference | NA | |
Yes | 40 (83.3) | 9 (20.5) | 0.05 | 0.01–0.20 | <.001 |
Complications | |||||
Cellulitis | |||||
No | 45 (97.8) | 37 (84.1) | Reference | NA | |
Yes | 1 (2.2) | 7 (15.9) | 8.51 | 0.93–78.19 | .023 |
OR, odds ratio; CI, confidence interval.